Plattsburgh, New York – SEPTEMBER 25, 2020: MEDISCA suspends CBD product line following DEA update defining synthetically derived CBD as a schedule I drug.

In compliance with a recent Drug Enforcement Administration (DEA) ruling, compounding industry leader MEDISCA has discontinued its product line containing synthetically derived CBD. Despite a letter to manufacturers in August 2019 stating that any CBD product with less than 0.3% THC is defined as “hemp” and is not a controlled substance, the DEA has announced that synthetic CBD will remain a schedule I drug. 

MEDISCA nor its clients holds a schedule I license; the company suspended its synthetic CBD products until further notice. 

Citing amendments to the Agricultural Improvement Act of 2018, the DEA stated that in order to qualify for exemption from the schedule I drug classification, the product must meet the definition of “hemp.” Under these statutes, CBD products only meet the definition of “hemp” if they are derived from the Cannabis sativa L. plant, and therefore, all synthetically derived tetrahydrocannabinols will remain a schedule I controlled substances. 

MEDISCA responded immediately to this ruling and removed all CBD related products from its website. “MEDISCA currently serves clients in over 50 countries around the world, all with unique laws and regulations on drug enforcement,” said Vanessa Verni, Senior Director, Regulatory Affairs, Legal and Quality at MEDISCA. “We strive for excellence in product quality and innovation, but also in strict adherence to all local laws governing the industry.”

The DEA currently defines schedule I drugs as having no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse. But as the market has shown that hemp products may play an essential role in treatment moving forward, MEDISCA will continue to research and develop innovative products to meet patient needs. 

Contact: Vanessa Verni

661 Route 3, Unit C

Plattsburgh, NY 12901

Medisca.com

1-800-932-1039

References:

https://www.deadiversion.usdoj.gov/fed_regs/rules/2020/fr0821.htm

https://www.federalregister.gov/documents/2020/08/21/2020-17356/implementation-of-the-agriculture-improvement-act-of-2018

https://www.dea.gov/drug-scheduling

About MEDISCA

Medisca is a global corporation with locations throughout North America, Australia, and Europe, that contributes to healthcare by leveraging strong partnerships that deliver customized solutions with an unwavering commitment to quality and innovation. Backed by 30+ years and a strong foundation in pharmaceutical compounding supply, Medisca is a business-to-business company that delivers comprehensive offerings by providing value, consistency, responsiveness, and loyalty. As Partners in Wellness, Medisca offers an unfailing devotion to improving lives across a multitude of needs and people. For more information visit www.medisca.com and follow us on LinkedIn, Facebook, Twitter, and YouTube.

Contact:

Adam Pinsky